Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) Short Interest Up 7,800.0% in July

Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) was the recipient of a large increase in short interest in July. As of July 31st, there was short interest totaling 7,900 shares, anincreaseof7,800.0% from the July 15th total of 100 shares. Currently,6.1% of the company’s stock are short sold. Based on an average trading volume of 2,800 shares, the short-interest ratio is presently 2.8 days. Based on an average trading volume of 2,800 shares, the short-interest ratio is presently 2.8 days. Currently,6.1% of the company’s stock are short sold.

Amplify Weight Loss Drug & Treatment ETF Trading Up 1.7%

THNR opened at $22.94 on Friday. The firm has a market cap of $2.98 million and a price-to-earnings ratio of 24.31. Amplify Weight Loss Drug & Treatment ETF has a 12 month low of $18.56 and a 12 month high of $28.19. The stock has a fifty day moving average price of $22.91 and a 200-day moving average price of $22.26.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Amplify Weight Loss Drug & Treatment ETF stock. Jane Street Group LLC increased its holdings in shares of Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) by 62.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 23,676 shares of the company’s stock after buying an additional 9,123 shares during the quarter. Jane Street Group LLC’s holdings in Amplify Weight Loss Drug & Treatment ETF were worth $534,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Amplify Weight Loss Drug & Treatment ETF Company Profile

The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.